Namodenoson for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an oral drug called Namodenoson for people with advanced pancreatic cancer that has not responded to previous treatments. The goal is to see if the drug can help slow the cancer's growth or improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that has spread or is not responding to treatment.
- You have tried at least one prior cancer treatment, or you choose not to take standard therapy.
- You are 18 years or older and have a performance status of 0 to 2 (able to care for yourself and up and about more than half the day).
- Your blood counts and organ function (kidneys, liver, bone marrow) are within the ranges required by the study.
- You are not pregnant, breastfeeding, and if applicable, you agree to use two effective birth control methods during the study and for one month after.
- You do not have a serious heart condition, active uncontrolled infection, another cancer needing treatment, or other major medical issues that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (SNV1521) combined with a RAS inhibitor for people with advanced pancreatic cancer. The goal is to see if this combination is safe and can help shrink or control the cancer.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug, XNW28012, for people with advanced pancreatic cancer that has worsened after two standard chemotherapy treatments. The drug targets a protein called tissue factor on cancer cells, which might help slow or stop the cancer's growth.
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.